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tem (based on DRG’s) and IMS-Portugal. The main cost
categories included are hospitalization, ambulatory care
and pharmaceuticals. Obesity population attributable
fraction (PAF) are calculated for ten co-morbidities. Rel-
ative risks are drawn from large-scale prospective inter-
national studies and prevalence data from national
sources. RESULTS: The direct cost of obesity in Portugal
in 1996 was estimated as PTE 46.2 billion. This corre-
sponds to 3.5% of annual health care expenditure, a share
larger than in 5 of the six countries where comparable
studies have been carried out (the exception being the U.S.).
The largest cost component is expenditure on pharmaceuti-
cals (43%), followed by hospitalization (29%) and ambu-
latory care (28%). Drug costs are attributable largely to cir-
culatory system pathologies, particularly hypertensive
diseases. Annually more than 35,000 inpatient episodes
are attributable to obesity and the problem is responsible
for over 2 million doctor visits. CONCLUSIONS: A con-
siderable proportion of Portuguese health spending is
used in treating obesity co-morbidities. Preventive and
therapeutic strategies that reduce obesity prevalence can
potentially bring about significant cost-savings. More re-
search is needed on the benefits and cost-effectiveness of
strategies aimed at reducing obesity.
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Colorectal cancer is the third most common cancer in
Canada with approximately 16,500 new cases in 1999.
Currently, 5-fluorouracil (5-FU) plus leucovorin is stan-
dard chemotherapeutic treatment. Raltitrexed, is a new
class of cytotoxic drug. OBJECTIVE: To measure from a
Canadian Ministry of Health perspective the economic
value of raltitrexed 3 mg/m2 once every three weeks and
425 mg/m2 5-FU plus 20 mg/m2 leucovorin for 5 days re-
peated every 28 days. Results of the study, a large North
American trial, are reported elsewhere. In this abstract,
results of Canadian patients are reported; specifically,
cost per quality adjusted survival. METHODS: Quality
adjustments were conducted by rewarding survival time
without toxicities and disease progression while penaliz-
ing time with toxicities or disease progression. Health-
care costs by type of resource and economic perspective
were collected from five centers that participated in the
clinical trial in Quebec and Ontario. RESULTS: 103 pa-
tients were eligible for analyses, 50 in the 5-FULV
group and 53 in the raltitrexed group. Without adjust-
ment for quality versus quantity of survival, the median
time to death from Kaplan Meier estimates were equiva-
lent, 496 and 493 days, respectively. Both time to pro-
gression and time with toxicities favored patients treated
with raltitrexed. Thus, quality adjusted survival favored
patients treated with raltitrexed, 269 versus 370 days at
the median. Direct drug cost favored 5-FULV, $130
versus $1005 for an average cost difference of $875;
nonetheless, the incremental cost per QALY for raltitrexed
was $3159 (95%CI: $1626–$4692). When other direct
medical costs were included raltitrexed became cost sav-
ing. CONCLUSIONS: Raltitrexed offers a more conve-
nient treatment regimen than 5-FU plus leucovorin and is
as effective while causing less toxicity.
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ACEIs reduce CHF mortality and hospitalization. How-
ever, commonly prescribed doses are often much lower
than target doses used in randomized clinical trials (RCTs)
and recommended by evidence-based practice guidelines.
In ATLAS, a RCT of high (32.5–35 mg) versus low (2.5–
5 mg) dose lisinopril in 3164 class II–IV CHF patients
with left ventricular ejection fraction 30% in 19 coun-
tries over 3 years, mortality risk was reduced 8% (P 
0.128); mortality and hospitalization risk was reduced
12% (P  0.002). OBJECTIVES: To assess the cost-ef-
fectiveness of high versus low dose lisinopril in the 1198
(high dose 592, low dose 606) US ATLAS patients.
METHODS: Hospital costs were estimated using man-
aged care diagnosis-related group reimbursement rates;
drug costs using average wholesale prices. Costs were dis-
counted at 3% per year. Statistical analyses were com-
puted using Wilcoxon rank-sum tests for hospitalizations
and T-test for log-transformed costs. RESULTS: High
dose lisinopril reduced CHF and total hospitalizations
(both P  0.050). In the US, hospitalizations per patient
were reduced 0.19 and hospitalization costs per patient
was reduced $950. Drug costs per patient increased
($1224 versus $688; P  0.001). Total costs per patient
decreased ($19,254 versus $19,709; P  0.038), result-
ing from decreased CHF hospitalizations. Cost savings
increased further when worldwide ATLAS patients and
hospitalizations were included. CONCLUSIONS: The in-
creased costs of high versus low dose lisinopril are more
than offset by cost savings from decreased CHF hospital-
izations. High dose lisinopril improves clinical outcomes
at reduced cost.
